Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy

利用先进生物材料克服疫苗相关缺氧以增强癌症免疫治疗

基本信息

  • 批准号:
    10612093
  • 负责人:
  • 金额:
    $ 45.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary Overcoming the poor efficacy of tumor cell vaccines will require enhancing activation of the immune system and preventing an immunosuppressive tumor microenvironment such as local hypoxia. In this proposal, we will address this critical need by engineering tumor cell vaccines with advanced oxygen-releasing biomaterials (O2- cryogels) to combat hypoxia-driven immunosuppression and improve antitumor immune responses in relevant mouse models of prostate cancer. Our preliminary data in mice indicate that: (i) O2-cryogels can reverse local hypoxia and restore the function of key immune cells (dendritic cells; DCs); (ii) once in the body, cryogel vaccines efficiently localize transplanted tumor cells, controllably release immunomodulatory factors, and recruit large numbers of DCs from the host; and (iii) elicit a specific and robust vaccine-induced T cell-mediated antitumor immunity. Here, we will optimize the characteristics of O2-cryogels for maximum antitumor efficacy and safety; and assess their ability to suppress the local hypoxic stress and improve DC recruitment, activation, and homing to the draining lymph nodes. Finally, we will test O2-cryogel vaccines in prophylactic and therapeutic mouse models of prostate cancer to determine their ability to induce specific, effective, and long-lasting antitumor immune responses. This proposal may have a sustained impact on the field by defining a new avenue of cancer immunotherapy that operates independently but synergizes with other therapies.
项目摘要 克服肿瘤细胞疫苗的不良效果将需要增强免疫系统的激活和 防止免疫抑制的肿瘤微环境,如局部缺氧。在这项提案中,我们将 通过使用先进的释氧生物材料(O2- 冷冻剂)对抗低氧诱导的免疫抑制,并改善相关的抗肿瘤免疫反应 前列腺癌的小鼠模型。我们在小鼠身上的初步数据表明:(I)O2-冷冻剂可以逆转局部 低氧和恢复关键免疫细胞(树突状细胞;树突状细胞)的功能;(2)一旦进入体内,冷冻疫苗 有效地定位移植的肿瘤细胞,可控地释放免疫调节因子,并招募大量 来自宿主的DC的数量;以及(Iii)诱导特异性和强效疫苗诱导的T细胞介导的抗肿瘤 豁免权。在这里,我们将优化O2-冷冻剂的特性,以实现最大的抗肿瘤效果和安全性; 并评估他们抑制局部低氧应激和改善DC招募、激活和归巢的能力 到引流的淋巴结处。最后,我们将在预防性和治疗性小鼠身上测试O2-冷冻胶疫苗 前列腺癌模型以确定其诱导特异、有效和持久的抗肿瘤作用的能力 免疫反应。这项提议可能会对该领域产生持续的影响,因为它定义了一种新的癌症途径 独立运作但与其他疗法协同的免疫疗法。

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Biomaterials Recycling: A Promising Pathway to Sustainability.
  • DOI:
    10.3389/fbiom.2023.1260402
  • 发表时间:
    2023-11
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Paulina Wiśniewska;M. Saeb;S. Bencherif
  • 通讯作者:
    Paulina Wiśniewska;M. Saeb;S. Bencherif
Endothelial glycocalyx sensitivity to chemical and mechanical sub-endothelial substrate properties.
Biomaterial-assisted local oxygenation safeguards the prostimulatory phenotype and functions of human dendritic cells in hypoxia.
  • DOI:
    10.3389/fimmu.2023.1278397
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
  • 通讯作者:
Synthesis and Characterization of Folic Acid-Functionalized DPLA-co-PEG Nanomicelles for the Targeted Delivery of Letrozole.
  • DOI:
    10.1021/acsabm.3c00041
  • 发表时间:
    2023-05-15
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Rostami, Neda;Gomari, Mohammad Mahmoudi;Abdouss, Majid;Moeinzadeh, Alaa;Choupani, Edris;Davarnejad, Reza;Heidari, Reza;Bencherif, Sidi A
  • 通讯作者:
    Bencherif, Sidi A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen Matthew Hatfield其他文献

Stephen Matthew Hatfield的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 45.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了